Company intelligence / Profile preview

atai Life Sciences

Ownership: Public · ATAI
Development stage: Other

Overview

Multiple clinical programs in progress. RL-007 is in Phase 2b for cognitive impairment associated with schizophrenia. GRX-917 is advancing to Phase 2 for anxiety disorders. PCN-101 (arketamine) failed to meet its primary endpoint in a clinical trial in January 2023. COMP360 (through investment in COMPASS Pathways) is in Phase 3 for treatment-resistant depression with data expected in summer 2024.

Therapeutic areas: Psychiatry
Modalities: Psychedelicshallucinogensentactogensnovel compounds
Industry: Biotech

Drug pipeline

4 assets

R-norketamine

Preclinical

3 more assets in the full pipeline.

Partnerships

COMPASS Pathways (22.4% stake)

Beyond the preview

Go deeper on atai Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atai Life Sciences.